跳至主要内容
临床试验/NCT02030548
NCT02030548终止不适用

Bleeding in Patients Undergoing Urgent CABG During Dual Antiplatelet Therapy Including the New P2Y12 Receptor Inhibitors Prasugrel and Ticagrelor

Medical University of Graz1 个研究点 分布在 1 个国家目标入组 144 人开始时间: 2013年11月最近更新:
适应症

试验速览

阶段
不适用
状态
终止
发起方
入组人数
144
试验地点
1
主要终点
calculated blood loss

研究概览

简要总结

The aim of the study is to evaluate surgery-related bleeding and mortality in patients needing acute coronary artery bypass grafting with or without valve replacement during dual antiplatelet therapy with aspirin and a P2Y12 receptor blocker (Clopidogrel, Prasugrel, Ticagrelor)

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • consecutive patients undergoing acute CABG with or without valve replacement within 7 days after last intake of dual antiplatelet therapy

排除标准

  • concomitant oral anticoagulants dialysis surgery employing hypothermic cardiac arrest

结局指标

主要结局

calculated blood loss

时间窗: until postoperative day 5

次要结局

  • mortality(from index surgery until one year after index surgery)

研究者

发起方
Medical University of Graz
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Bleeding in Patients Undergoing CABG (Coronary... | 临床试验